B dot Medical
B dot Medical is a Japanese medical device startup that develops the Phemto® ultra-compact proton therapy system using proprietary superconducting magnet technology, selling capital equipment to hospitals in Japan and the ASEAN region.
- Company typePrivate
- Founded2017
- HeadquartersEdogawa, Japan
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What B dot Medical does
B dot Medical Inc. is a Tokyo-based medical device startup founded in 2017 by Takuji Furukawa, a former researcher at Japan's National Institute of Radiological Sciences (NIRS), together with six colleagues. The company develops and manufactures the Phemto® ultra-compact proton therapy system, which uses a proprietary non-rotating Magnetic Gantry with superconducting electromagnets to reduce system height to roughly one-third that of conventional proton therapy systems and cut installation costs by approximately half. This miniaturization enables proton therapy deployment in existing hospital radiotherapy rooms rather than dedicated large-scale facilities, targeting the universe of urban hospitals that previously could not accommodate conventional systems given Japan's existing base of only 19 proton therapy facilities serving over 1 million new cancer patients annually.
The product portfolio comprises the Phemto® treatment system (PMDA approval received November 2023) and the Throup™ self-propelled treatment table (approval March 2024), supplemented by particle therapy consulting services and treatment planning software integration through a partnership with RaySearch Laboratories. Revenue mechanics rely on capital equipment sales to hospitals and medical institutions, with distribution via direct enterprise sales in Japan and channel partners (notably Olba Healthcare Holdings) for Thailand and ASEAN markets. Pricing is not publicly disclosed, though management claims approximately 50% installation cost reduction versus conventional systems.
The company has raised JPY 6.8 billion cumulatively across multiple equity and debt rounds, most recently a JPY 1.3 billion Series B2 in October 2025. To date it has signed two installation agreements: Edogawa Hospital Group for what would be Tokyo's first proton therapy facility, and Thammasat University in Thailand for the first ASEAN installation. Headcount is approximately 60 employees. The company remains pre-commercial deployment, with no revenue disclosed in available sources.
B dot Medical firmographics
Firmographics- Name
- B dot Medical
- Legal name
- B dot Medical Inc.
- Website
- https://bdotmed.co.jp
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- B dot Medical is a Japanese medical device startup that develops the Phemto® ultra-compact proton therapy system using proprietary superconducting magnet technology, selling capital equipment to hospitals in Japan and the ASEAN region.
- Ownership category
- akta.pro rank
B dot Medical industry classification
Industry- Product category
- Radiation Oncology / Proton Therapy Systems
- NAICS
- Irradiation Apparatus Manufacturing (334517), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
- akta.pro primary industry
- Radiation Oncology (HLAKAFAC)
Keywords
Where B dot Medical is headquartered
LocationHeadquarters
- HQ city
- Edogawa
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
B dot Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Ultra-compact Proton Therapy System Sales: Sale of Phemto ultra-compact proton therapy cancer treatment systems to hospitals and medical institutions. The company obtained regulatory approval (PMDA) in November 2023 and is now commercializing the system for deployment at hospital sites.
- Treatment System Accessories and Software: Sales of related treatment accessories including the Throup self-propelled treatment table (regulatory approval obtained March 2024), and software solutions in partnership with RaySearch
- Particle Therapy Consulting Services: Technical consulting services for particle therapy facility design, manufacturing, and treatment start-up support, leveraging advanced technology and know-how developed at NIRS
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
B dot Medical product offering
Product offeringCore offering
B dot Medical designs, manufactures, and sells the Phemto® ultra-compact proton therapy system, which uses a proprietary non-rotating Magnetic Gantry with superconducting magnets to deliver cancer radiotherapy in a footprint comparable to standard LINAC systems. The company also offers the Throup™ self-propelled treatment table as a complementary accessory, integrates its systems with RaySearch treatment planning software, and provides particle therapy consulting services for facility design, manufacturing, and treatment start-up.
Product overview
B dot Medical is a medical device startup that has developed an ultra-compact proton therapy system. The core product is the Phemto® ultra-compact proton therapy system, which uses proprietary non-rotating gantry technology with superconducting magnets to achieve significant size reduction compared to conventional proton therapy systems. The company also offers the Throup™ treatment table as an accessory. B dot Medical provides complete proton therapy solutions including the treatment system, treatment planning software integration (via RaySearch partnership), and consulting services for particle therapy facility implementation.
Differentiator
Problem solved
Functional benefit
Products and services
- Phemto® Ultra-Compact Proton Therapy System Ultra-compact proton therapy cancer treatment system using a proprietary non-rotating Magnetic Gantry with superconducting magnets. Sized at approximately one-third the height of conventional proton therapy systems (LINAC-equivalent), it is designed for installation in existing hospital radiotherapy departments and enables high-speed scanning and respiratory-gated irradiation for moving tumors.
- Throup™ (シャトル治療台) Self-Propelled Treatment Table Self-propelled treatment table designed to improve treatment room efficiency and patient positioning accuracy for proton therapy, sold as a complementary accessory to the Phemto system.
- Particle Therapy Consulting Services Technical consulting services for particle therapy facility design, manufacturing, and treatment start-up support, leveraging advanced technology and know-how developed at NIRS.
Quantifiable outcome
- System size reduced to approximately one-third conventional height (from 12 meters to LINAC-equivalent)
- +2 more outcomes
Companies that use B dot Medical
Customer profileNamed customers3 records
Segments1 record
Ideal customer profiles1 record
B dot Medical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature4 records
B dot Medical partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Heron Neutron Medical Corp.coreTaiwan's BNCT (Boron Neutron Capture Therapy) manufacturer. Signed MOU for strategic business partnership toward promoting proton therapy and BNCT integration in cancer treatment.
- Yamagata UniversityminorJoint research to elucidate optimal treatment planning methods in radiotherapy using X-rays, proton beams, and heavy ion beams. B dot Medical previously provided technical consulting for Yamagata's heavy ion therapy system.
- RaySearch Laboratories ABcoreStrategic collaboration for development and validation of integrations between B dot Medical's ultra-compact proton therapy system and RaySearch's treatment planning system and oncology information system. RaySearch serves over 100 hospitals globally.
- Thammasat UniversitycoreMOU for installation of ultra-compact proton therapy system in Thailand. First installation in ASEAN region. Clinical trials for system approval in Thailand will be led by Thammasat University.
- Olba Healthcare Holdings / THAI OLBA Healthcare Co., Ltd.coreSales alliance for Thailand and ASEAN markets. Olba Healthcare established Thai subsidiary in 2023 to support B dot Medical's business development in the region.
- Edogawa Hospital Group (Jinseisha)coreBasic agreement for installation of ultra-compact proton therapy system at Edogawa Medicare Hospital, marking Tokyo's first proton therapy facility. Represents first commercial deployment in Japan.
- National Center for Child Health and Development (NCCHD)minorNEDO Product Commercialization Alliance for 'Smart Radiotherapy Room' development. Aims to increase the value of proton therapy and create a society where cancer patients can receive proton therapy worldwide.
- Osaka University Nuclear Physics Research CenterminorJoint research for principle demonstration of ultra-compact proton therapy system. Conducted proof of concept experiments using AVF cyclotron beam at the center's accelerator facility.
- Medical Advisory Board MembersminorAdvisory board comprising leading radiation oncologists including Dr. Hirohiko Tsujii (QST Hospital), Dr. Tetsuo Akimoto (National Cancer Center East), and Dr. Hiroshi Fuji (NCCHD) providing clinical perspective on product development.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
B dot Medical competitors and assessment
Company assessmentDirect peers
- Mevion Medical Systems: Mevion is the closest direct peer: a US-based proton therapy manufacturer focused on compact, single-room systems (e.g., MEVION S250i with HYPERSCAN). Like B dot Medical, Mevion pursues a miniaturization thesis to broaden hospital access to proton therapy, making it the most comparable competitor in product positioning and customer profile.
- ProTom International: ProTom International is a US-based proton therapy company developing compact, lower-cost systems, directly comparable to B dot Medical's miniaturization thesis. Both target the same niche of hospitals seeking affordable, smaller-footprint proton therapy installations.
Broad incumbents
- Hitachi High-Tech (Hitachi): Hitachi is the dominant Japanese proton therapy incumbent via its PROBEAT system and long-standing hospital installations. As a Japan-based legacy player with deep clinical relationships, it competes head-on with B dot Medical for domestic hospital procurements while offering rotating gantry systems rather than B dot Medical's compact superconducting approach.
- Sumitomo Heavy Industries: Sumitomo Heavy Industries manufactures proton therapy systems and has supplied multiple Japanese proton therapy facilities. It is a Japan-based incumbent with established manufacturing and service infrastructure, representing another domestic competitor for hospital proton therapy contracts.
- IBA (Ion Beam Applications): IBA is the global market leader in proton therapy, offering the ProteusPLUS and ProteusONE systems installed across dozens of hospitals worldwide. Its single-room ProteusONE competes on the same compact-proton premise as B dot Medical, though with a different (rotating gantry) architecture and a much larger installed base.
- Varian (a Siemens Healthineers company): Varian's ProBeam proton therapy system, now under Siemens Healthineers, competes globally with B dot Medical across the same hospital customer base. As the world's largest radiation oncology vendor, Varian brings cross-selling power, treatment planning software, and service infrastructure that B dot Medical must compete against or partner around.
- Mitsubishi Electric: Mitsubishi Electric is another Japan-based industrial conglomerate with a particle therapy systems business, supplying rotating-gantry proton and heavy-ion therapy installations. It competes for Japanese hospital procurements and possesses the R&D resources to respond to B dot Medical's miniaturization approach.
- Elekta: Elekta is a leading global radiation therapy vendor specializing in linear accelerators (LINAC) and the Unity MR-LINAC. While Elekta does not sell proton therapy systems, it competes with B dot Medical indirectly for hospital radiotherapy capital budgets, since hospitals frequently choose between upgrading LINAC capacity versus installing a proton system.
- Accuray: Accuray manufactures the CyberKnife and TomoTherapy radiation therapy systems and competes for the same hospital radiotherapy procurement dollars. Like Elekta, it is an indirect competitor that defines the LINAC alternative against which B dot Medical's compact proton offering must justify its premium.
Others
- RaySearch Laboratories: RaySearch Laboratories is a Swedish treatment planning software vendor (RayStation, RayCare) used by 100+ hospitals and a stated technology partner of B dot Medical. It is not a direct competitor but a critical ecosystem enabler whose planning software integrates with B dot Medical's proton system.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
B dot Medical social profiles
Digital presenceB dot Medical compliance and trust
Trust signalCompliance1 record
B dot Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
B dot Medical leadership team
Management profileNumber of profiles
Profiles8 records
B dot Medical funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
B dot Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about B dot Medical
What does B dot Medical do?
B dot Medical designs, manufactures, and sells the Phemto® ultra-compact proton therapy system, which uses a proprietary non-rotating Magnetic Gantry with superconducting magnets to deliver cancer radiotherapy in a footprint comparable to standard LINAC systems. The company also offers the Throup™ self-propelled treatment table as a complementary accessory, integrates its systems with RaySearch treatment planning software, and provides particle therapy consulting services for facility design, manufacturing, and treatment start-up.
Is B dot Medical a public or private company?
B dot Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was B dot Medical founded?
B dot Medical was founded in 2017. It employs 51 to 100 people.
Where is B dot Medical based?
B dot Medical is headquartered in Edogawa, Japan, in the Asia region.
How does B dot Medical make money?
Three revenue lines are on record. Ultra-compact Proton Therapy System Sales are the primary driver. The others are treatment System Accessories and Software and particle Therapy Consulting Services.
Who are B dot Medical's main competitors?
Direct peers on record are Mevion Medical Systems and ProTom International. Broad incumbents are Hitachi High-Tech (Hitachi), Sumitomo Heavy Industries, IBA (Ion Beam Applications), Varian (a Siemens Healthineers company), Mitsubishi Electric, Elekta and Accuray. RaySearch Laboratories is listed as an others.
Does B dot Medical have an API?
No public API is recorded for B dot Medical.
What industry is B dot Medical in?
B dot Medical's product category is Radiation Oncology / Proton Therapy Systems. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology. Its NAICS code is 334517 and its SIC code is 3845.